Study guide
3.4 Patient Counseling, Prospective DUR & OBRA '90 Mandates
Mississippi MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Mississippi MPJE Overview
1.1 Mississippi MPJE Format, Logistics & Official Blueprint 1.2 Study Strategy & Federal vs. Mississippi Legal Hierarchy 1.3 Federal & State Regulatory Authorities & Oversight
2 Chapter 2: Mississippi Pharmacy Governance, Board Structure & Licensure
2.1 Mississippi Board of Pharmacy: Structure, Authority & Operations 2.2 Pharmacist Licensure, Examination, Reciprocity & Continuing Education 2.3 Pharmacy Interns, Externs & Preceptor Requirements 2.4 Pharmacy Technicians: Registration, Scope & Supervision Ratios 2.5 Disciplinary Proceedings, Impairment & Current Monitoring
3 Chapter 3: Pharmacist Practice Standards & Prescribing Authority
3.1 Prescription Requirements, Formats & Electronic Prescribing (EPCS) 3.2 Prescriptive Authority in Mississippi: Physicians, Mid-Level Practitioners & Out-of-State 3.3 Collaborative Drug Therapy Management (CDTM) & Institutional Protocols 3.4 Patient Counseling, Prospective DUR & OBRA '90 Mandates 3.5 HIPAA, Patient Privacy & Confidentiality of Pharmacy Records
4 Chapter 4: Controlled Substances: Scheduling, Ordering & Security
4.1 Federal & Mississippi Controlled Substance Scheduling 4.2 DEA Registration, Mississippi Permitting & Physical Security 4.3 Schedule II Ordering: Single-Sheet DEA Form 222 & Electronic CSOS 4.4 Controlled Substance Inventories: Mississippi Annual Mandate 4.5 Controlled Substance Disposal (DEA Form 41) & Theft/Loss Reporting Protocols
5 Chapter 5: Dispensing Controlled Substances & Prescription Processing
5.1 Schedule II Prescriptions: Issuance, Emergency Oral Dispensing & Sequential Prescriptions 5.2 Partial Filling of Controlled Substances: CARA, Out-of-Stock & Long-Term Care 5.3 Schedule III–V Prescriptions: Refill Limitations, Authorizations & Expirations 5.4 Prescription Transfers: Federal & Mississippi Requirements 5.5 Corresponding Responsibility, Red Flags & Legitimate Medical Purpose
6 Chapter 6: Mississippi Prescription Monitoring Program & Public Health Mandates
6.1 Mississippi Prescription Monitoring Program (MS PMP Gateway): Mandates & 24-Hour Reporting 6.2 Opioid Prescribing Limits, MME Calculations & Acute Pain Restrictions 6.3 Naloxone Standing Order, Overdose Prevention & Harm Reduction Dispensing 6.4 Behind-the-Counter Sales: Pseudoephedrine & Ephedrine Regulations 6.5 Pharmacist Immunization Authority & Protocol Administration in Mississippi
7 Chapter 7: Pharmacy Operations, Permits & Facilities
7.1 Community Pharmacy Permits, Pharmacist-in-Charge (PIC) Duties & Staffing 7.2 Institutional & Hospital Pharmacy Practice Regulations 7.3 Automated Medication Systems, Remote Dispensing & Telepharmacy 7.4 Non-Resident (Mail-Order) Pharmacies, Licensure & Wholesale Distributors 7.5 Drug Supply Chain Security Act (DSCSA), Track-and-Trace & Product Quarantines
8 Chapter 8: Compounding Standards, Safety & Product Selection
8.1 Non-Sterile Compounding (USP <795>): Categories, Beyond-Use Dating & Quality Assurance 8.2 Sterile Compounding (USP <797>): Cleanrooms, ISO Classifications & Aseptic Protocols 8.3 Hazardous Drug Handling (USP <800>): Engineering Controls, PPE & Spill Protocols 8.4 Generic Drug Substitution, FDA Orange Book & Purple Book Biosimilars 8.5 Repackaging, Unit-Dose Beyond-Use Dating & FDA Drug Recall Classifications
9 Chapter 9: Review, Clinical Scenarios & High-Yield Calculations
9.1 High-Yield Scenario Review: Resolving Complex Federal vs. Mississippi Legal Conflicts 9.2 Pharmacy Law Calculations: DEA Verification, Days Supply, Limits & Ratios 9.3 Rapid-Fire Master Review: Key Timelines, Quantities, Retention Periods & Forms 9.4 Exam Day Strategy, Computer-Adaptive Pacing & Distractor Elimination 9.5 High-Frequency MPJE Pitfalls & Distractor Traps
3.4 Patient Counseling, Prospective DUR & OBRA '90 Mandates
Key Takeaways Explain This Topic AI
Prospective DUR includes overutilization, underutilization, therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect dose or duration, drug-allergy interactions, and clinical abuse or misuse.
A meaningful offer to counsel must be made when required; an agent may convey the offer, but counseling itself is performed by the pharmacist or authorized supervised intern.
Counseling content is tailored to significant information such as drug and description, route and administration, precautions, interactions, adverse effects, monitoring, storage, and missed doses.
For delivery, the pharmacy provides printed information that includes pharmacy contact information and the counseling subjects required by Article VIII.
A patient may refuse counseling; current Article VIII does not create a universal legal requirement to record every refusal, although a pharmacy may document it as prudent policy.
Last updated: August 2026
Prospective DUR and Patient Counseling
Mississippi Article VIII makes prospective drug utilization review and patient counseling core pharmacist responsibilities. OBRA ’90 established Medicaid counseling and DUR expectations, while Mississippi’s regulation supplies the practice rule applied in the pharmacy. Do not confuse the offer with the counseling itself or shorten DUR to an inaccurate six-item list.
Prospective DUR
Before dispensing, the pharmacist reviews the patient profile and available information for:
- overutilization and underutilization ;
- therapeutic duplication;
- drug-disease contraindications;
- drug-drug interactions;
- incorrect dosage or duration of treatment;
- drug-allergy interactions; and
clinical abuse or misuse.
Overutilization and underutilization are separate concepts even though they appear together in the rule. Counting the list as only six categories omits a required screening dimension. The review is prospective: discovering a contraindication after release does not satisfy the duty.
A computer alert supports but does not replace pharmacist judgment. The pharmacist evaluates clinical significance using dose, timing, diagnosis, organ function, prior use, prescriber intent, and patient factors. A resolved alert may be documented with the basis for dispensing. An unresolved serious problem requires prescriber or patient communication, modification, delay, or refusal as appropriate.
Offer and provider
When counseling is required, the pharmacy must make a meaningful offer . A pharmacist’s agent may ask whether the patient wants to speak with the pharmacist, but the agent may not provide the professional counseling. Counseling is performed by the pharmacist; a registered intern may participate within authorized supervision.
A sign on the counter, a prechecked refusal box, or “call if you have questions” may be inadequate if the process does not genuinely give the patient access to the pharmacist. At the same time, the law does not force a competent patient to listen. The patient or caregiver may decline.
Article VIII should not be embellished with a universal command that every refusal must be entered into a particular electronic field or written log. Documentation is often excellent risk-management policy, and a pharmacy may require it, but an exam answer should distinguish that policy from the current regulatory text.
Counseling substance
Counseling is individualized to significant information. Depending on the prescription, cover the drug name and description; dosage form, dose, route, and duration; intended use and expected action; special directions; precautions and contraindications; significant interactions; common or serious adverse effects and response; self-monitoring; proper storage; refill information; and missed-dose instructions. The pharmacist may supplement oral counseling with written material but should not merely hand over a leaflet when discussion is needed.
Use professional judgment for refills and familiar maintenance therapy, but a changed strength, new interaction, adherence problem, high-risk drug, or patient question can make counseling significant even if the prescription is labeled a refill.
Delivery and remote pickup
When a prescription is delivered rather than handed to the patient at the pharmacy, Mississippi requires printed information that tells the patient how to contact the pharmacy and addresses the counseling information required by the rule. The regulation should not be converted into an invented “toll-free number” requirement for every delivery if it requires the pharmacy’s name, address, and telephone contact.
If counseling occurs by telephone or video, protect privacy and ensure the person can ask questions. A technician may facilitate connection but cannot answer clinical questions.
Exam sequence
Apply four gates: Was prospective DUR complete? Was a meaningful offer made? Did an authorized professional provide any counseling? Was content adequate for the patient and drug? A patient’s refusal ends the counseling conversation but does not erase DUR, labeling, verification, or the pharmacist’s duty to intervene in a dangerous prescription.
DUR and counseling example
A new trimethoprim-sulfamethoxazole prescription reaches a profile containing warfarin and a documented sulfonamide allergy. DUR identifies both a drug-drug interaction and an allergy problem before dispensing. The pharmacist gathers reaction history, indication, INR plan, and prescriber rationale, then resolves or refuses the order and records the outcome. A patient’s later refusal to hear counseling does not authorize ignoring either DUR issue.
For home delivery, include written pharmacy contact and significant counseling information and make pharmacist access workable. If the patient calls about bleeding or rash, a technician transfers the call rather than interpreting the symptoms. A leaflet can reinforce dosing and warnings, but it cannot substitute for pharmacist intervention when the profile reveals an unresolved hazard.